Comparing Monjuvi vs Zynlonta
| Monjuvi (tafasitamab) | Zynlonta (loncastuximab tesirine) |
|
|---|
| Monjuvi (tafasitamab) | Zynlonta (loncastuximab tesirine) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Diffuse Large B-Cell Lymphoma, Follicular Lymphoma. Monjuvi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Diffuse Large B-Cell Lymphoma. Zynlonta may also be used for purposes not listed in this medication guide. |
Related suggestions Diffuse Large B-Cell Lymphoma
Popular comparisons
|
|||||||||||||||
| More about Monjuvi (tafasitamab) | More about Zynlonta (loncastuximab tesirine) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Monjuvi has an average rating of 5.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Monjuvi side effects |
View all Zynlonta side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Monjuvi prices |
View all Zynlonta prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
408 hours |
499.2 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 321 drugs are known to interact with Monjuvi:
|
A total of 529 drugs are known to interact with Zynlonta:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
April 23, 2021 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.